Abstract
Merkel cell carcinoma (MCC) is the most aggressive cutaneous tumor without clearly defined treatment. Although MCC has a high propensity for metastasis, little is known about the underlying mechanisms that drive MCC invasion and metastatic progression. MMP-9 has been shown to play a detrimental role in many metastatic human cancers, including melanoma and other nonmelanoma skin cancers. Our study shows that MCV sT-mediated MMP-9 activation is driven through the LSD, a known E3 ligase-targeting domain, in MCC. MMP-9 may serve as the biochemical culprit to target and develop a novel approach for the treatment of metastatic MCC.
All Related Versions
Funding Information
  • HHS | NIH | National Cancer Institute (T32 CA060395)
  • Pennsylvania Department of Health (Tobacco CURE Funds)
  • American Cancer Society (IRG-17-175-04)

This publication has 66 references indexed in Scilit: